Neuroendocrine tumor targeting: Study of novel gallium-labeled somatostatin radiopeptides in a rat pancreatic tumor model

2002 ◽  
Vol 98 (6) ◽  
pp. 930-937 ◽  
Author(s):  
Sylvie Froidevaux ◽  
Alex N. Eberle ◽  
Martine Christe ◽  
Lazar Sumanovski ◽  
Axel Heppeler ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Tumor Targeting ◽  
Pancreatic Tumor ◽  
Tumor Model

Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model

2018 ◽  
Vol 16 (3) ◽  
pp. 496-507 ◽  
Author(s):  
Daniel Benten ◽  
Yasmin Behrang ◽  
Ludmilla Unrau ◽  
Victoria Weissmann ◽  
Gerrit Wolters-Eisfeld ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Tumor Model ◽  
Pancreatic Neuroendocrine Tumor ◽  
Well Differentiated

scholarly journals Strong antitumor efficacy of a pancreatic tumor-targeting oncolytic adenovirus for neuroendocrine tumors

2017 ◽  
Vol 6 (10) ◽  
pp. 2385-2397 ◽  
Author(s):  
Yuki Yamamoto ◽  
Masaki Nagasato ◽  
Yosei Rin ◽  
Marina Henmi ◽  
Yoshinori Ino ◽  
...  
Keyword(s):  
Neuroendocrine Tumors ◽  
Tumor Targeting ◽  
Pancreatic Tumor ◽  
Oncolytic Adenovirus ◽  
Antitumor Efficacy

scholarly journals Visible Drug Delivery by Supramolecular Nanocarriers Directing to Single-Platformed Diagnosis and Therapy of Pancreatic Tumor Model

2010 ◽  
Vol 70 (18) ◽  
pp. 7031-7041 ◽  
Author(s):  
Sachiko Kaida ◽  
Horacio Cabral ◽  
Michiaki Kumagai ◽  
Akihiro Kishimura ◽  
Yasuko Terada ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Pancreatic Tumor ◽  
Tumor Model ◽  
Diagnosis And Therapy

scholarly journals Can DCE-MRI Explain the Heterogeneity in Radiopeptide Uptake Imaged by SPECT in a Pancreatic Neuroendocrine Tumor Model?

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e77076 ◽  
Author(s):  
Karin Bol ◽  
Joost C. Haeck ◽  
Harald C. Groen ◽  
Wiro J. Niessen ◽  
Monique R. Bernsen ◽  
...  
Keyword(s):  
Neuroendocrine Tumor ◽  
Tumor Model ◽  
Pancreatic Neuroendocrine Tumor ◽  
Dce Mri

scholarly journals Enriched pharmacokinetic behavior and antitumor efficacy of thymoquinone by liposomal delivery

Nanomedicine ◽  
2021 ◽  
Vol 16 (8) ◽  
pp. 641-656
Author(s):  
Hari Krishnareddy Rachamalla ◽  
Santanu Bhattacharya ◽  
Ajaz Ahmad ◽  
Kathyayani Sridharan ◽  
Vijay Sagar Madamsetty ◽  
...  
Keyword(s):  
Pancreatic Tumor ◽  
Tumor Model ◽  
Volume Of Distribution ◽  
Liposomal Formulation ◽  
Ethanol Injection ◽  
Anticancer Efficacy ◽  
Anticancer Effects ◽  
Systemic Bioavailability ◽  
Pharmacokinetic Behavior

Background: Thymoquinone (TQ) has potential anti-inflammatory, immunomodulatory and anticancer effects but its clinical use is limited by its low solubility, poor bioavailability and rapid clearance. Aim: To enhance systemic bioavailability and tumor-specific toxicity of TQ. Materials & methods: Cationic liposomal formulation of TQ (D1T) was prepared via ethanol injection method and their physicochemical properties, anticancer effects in orthotopic xenograft pancreatic tumor model and pharmacokinetic behavior of D1T relative to TQ were evaluated. Results: D1T showed prominent inhibition of pancreatic tumor progression, significantly greater in vivo absorption, approximately 1.5-fold higher plasma concentration, higher bioavailability, reduced volume of distribution and improved clearance relative to TQ. Conclusion: Encapsulation of TQ in cationic liposomal formulation enhanced its bioavailability and anticancer efficacy against xenograft pancreatic tumor.

scholarly journals Fe2P nanorods based photothermal therapy combined with immune checkpoint inhibitors for pancreatic cancer

Nanophotonics ◽  
2021 ◽  
Vol 0 (0) ◽  
Author(s):  
Shanshan Liu ◽  
Jiawen He ◽  
Ruixiang Song ◽  
Mengmeng Zhang ◽  
Lianghao Huang ◽  
...  
Keyword(s):  
Pancreatic Cancer ◽  
Cell Death ◽  
Photothermal Therapy ◽  
Pancreatic Tumor ◽  
Local Treatment ◽  
Advanced Pancreatic Cancer ◽  
Tumor Model ◽  
Pancreatic Tumors ◽  
Tumor Cell Death ◽  
Primary Tumors

Abstract Treatment of pancreatic cancer is faced with great difficulties and challenges due to high lethality and metastasis. Synergism of targeted therapy and immunotherapy has been considered as ideal strategy to both eliminate primary tumors and control metastases. For the treatment of advanced pancreatic cancer, we demonstrated a local photothermal therapy (PTT) following administration of monoclonal antibody of programmed death ligand 1 (αPD-L1). Fe2P nanorods were employed as a Fenton agent and photothermal agent, which modified with DSPE-PEG2000-Mal for improved biocompatibility and Mal mediated-antigen presentation. Under a low dose laser irradiation at 980 nm, Fe2P-PEG-Mal nanorods (NRs) mediated PTT could induce immunogenic tumor cell death that can cause dendritic cells (DCs) infiltration and maturation. In a bilateral pancreatic tumor model, the local treatment of NRs-PTT on primary tumor could cause the increased infiltration of cytotoxic T lymphocytes (CTLs) and decreased residential of M2 macrophages in untreated distal tumors. Furthermore, subsequently intervened αPD-L1 could enhance cell death triggered by CTLs in distal tumors through reversing immunosuppression. An orthotopic pancreatic tumor model was used to further confirm the therapeutic outcome. Finally, the combination of NRs based PTT and αPD-L1 based immunotherapy was able to significantly eliminate orthotopic pancreatic tumors and reduce mesentery metastases. Thus, the strategy may provide a more effective treatment for pancreatic cancer.

Sign in / Sign up

Export Citation Format

Share Document